NCT05189548View on ClinicalTrials.gov

To Evaluate the Safety and Primary Immunogenicity of Cell-free (Three-component) Combination Vaccine for Phase I Immunogenicity in Children and Infants

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

December 10, 2021

Primary Completion Date

April 30, 2022

Study Completion Date

September 30, 2022

Conditions
Safety、Immunogenicity
Interventions
BIOLOGICAL

A single-center and single-arm design was used to evaluate the safety and preliminary immunogenicity of the adsorbed cell-free leukiche (three-component) combination vaccine

A single-center and single-arm design was used to evaluate the safety and preliminary immunogenicity of the adsorbed cell-free leukiche (three-component) combination vaccine

Trial Locations (1)

621100

RECRUITING

Santai County Center for Disease Control and Prevention, Mianyang

Sponsors
All Listed Sponsors
lead

Changchun BCHT Biotechnology Co.

INDUSTRY

NCT05189548 - To Evaluate the Safety and Primary Immunogenicity of Cell-free (Three-component) Combination Vaccine for Phase I Immunogenicity in Children and Infants | Biotech Hunter | Biotech Hunter